David Hutton, Managing Editor, Ophthalmology Times

The global survey revealed similar challenges for individuals with unilateral and bilateral geographic atrophy.

Aurion Biotech announced that Phase 1/2 CLARA trial of AURN001 for corneal edema demonstrated significant dose-dependent efficacy, especially in the high-dose group, with favorable safety and tolerability profiles.

The University of Colorado study found that patient visits for irritation and allergies more than double during high particulate matter levels, emphasizing the need for proactive clinical strategies.

Korean researchers developed an AI model using OCT images to predict neovascular AMD treatment outcomes after anti-VEGF injections.

Building on previous RPE patch research, the research team aims to advance the therapy to early-stage human trials.

Tenpoint Therapeutics and Visus Therapeutics have merged to focus on aging-related ocular conditions, with key products including BRIMOCHOL PF for presbyopia and therapies for cataracts and geographic atrophy.

The study evaluates Duravyu’s efficacy, durability, and re-dosing every 6 months in both treatment-naïve and previously treated patients.

The ELIOS system is a laser-based technology that offers a new approach to treating glaucoma, particularly in conjunction with cataract surgery.

The company begins phase 1 trials of oral GAL-101, targeting amyloid beta aggregation for potential treatment of dry AMD, glaucoma, and neurodegenerative eye diseases.

Key findings from the data include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating significant potential for the treatment option.

The company noted that new OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal degeneration.

A recent paper sparks concerns over inadequate screening and management, especially among Black and Hispanic youths, according to its authors.

Published data from a pair of Phase 3 clinical trials demonstrated a reversal of pharmacologically-induced mydriasis with a favorable safety profile, according. to the company.

The FDA and Palatin agreed on a clear regulatory path for PL9643 NDA submission in DED. The company hopes to start patient enrollment to start in the fourth quarter of calendar year 2024.

A team of researchers from Johns Hopkins Medicine and the University of Wisconsin-Madison conducted a study on the application of autonomous artificial intelligence LumineticsCore and testing for diabetic eye disease.

Smart contact lenses can be used to correct vision, monitor the health of the user, and flag and treat diseases for patients diagnosed with chronic health conditions such as glaucoma and diabetes.

Researchers at the Medical College of Georgia at Augusta University are teaming up with Polaris Dawn to investigate how eye changes astronauts may experience during spaceflight could lead to multiple symptoms once back on Earth.

The product candidate is a modifier gene therapy for broad retinitis pigmentosa indication.

Topline results from the trial continue to be expected in H2 2025.

A new analysis by researchers at the National Institutes of Health shows the benefit of taking AREDS2 formula in late AMD.

According to the company, the tuck-in acquisition will help expand its surgical presence in the United States and contribute to its leading position in dry eye.

The 2-year Phase III data demonstrates Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.

FYSX is the first non-pharmacological, non-surgical treatment designed to lower IOP for glaucoma patients, according to a news release.

According to Genentech, faricimab-svoa is the first and only syringe that is prefilled with an FDA-approved bispecific antibody to treat wet AMD, DME and RVO.

The study evaluates the efficacy, safety, and tolerability of 2 dose levels of AGTC-501 for the treatment of X-linked retinitis pigmentosa.

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

The company plans to finalize its Phase 3 development plans following an End-of-Phase 2 meeting with the FDA.

Researchers examined data of more than 200,000 people, 121,523 of which had no history of AMD.

The study demonstrated sustained safety and efficacy of cyclosporine ophthalmic solution (Vevye) 0.1%, with many patients now entering their sixth refill cycle, according to the company.

The Early Detection of Vision Impairment in Children (EDVI) Act was recently introduced in the US House of Representatives with the goal of improving access, diagnosis, and treatment for children ages 2 to 17, according to Prevent Blindness.